- AuthorisedTherapeutic use (Phase IV)
NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial
This study looks at how certain blood pressure and heart medications might help people with type 2 diabetes, who haven't had heart problems before, to avoid future heart issues. It focuses on a specific blood marker (NT-proBNP) to guide treatment.
For: Diabetes mellitus Type 2Spain · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure
This study is looking into a new medication called XXB750 for people with heart failure. It hopes to see how well it works, what dose is best, and if it's safe compared to a dummy treatment or existing medicines.
For: Heart FailureNetherlands · Italy · Bulgaria - AuthorisedTherapeutic confirmatory (Phase III)
Early start corticosteroids versus standard care (RASBs followed by corticosteroids) for proteinuria in Immunoglobulin A Nephropathy (IgAN) patients with active renal lesions identified by kidney biopsy and RASBs combined with corticosteroids versus sodium-glucose cotransporter2 inhibitor combined with RASBs for proteinuria and renal function in IgAN patients with chronic renal lesions identified by kidney biopsy. A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY BIOPSY FINDINGS IN IgAN PATIENTS (CLIgAN)
This study is looking at new ways to treat IgA nephropathy (IgAN), a kidney disease. It compares different medications like steroids and dapagliflozin to see how well they reduce protein in the urine and protect kidney function in people with IgAN, depending on their kidney biopsy results.
For: Idiopathic IgA nephropathy (IgAN)Italy